Listed

CareCloud, Inc.: Form 10-Q for the period ended Mar 31, 2023

Filed with the SEC on May 4, 2023 and accepted by EDGAR at May 4, 2023, 16:30 ET.

Share

Management's discussion and analysis

As filed, 44,592 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following is a discussion of our consolidated financial condition and results of operations for the three months ended March 31, 2023 and 2022, and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Consolidated Financial Statements and related notes beginning on page 4 of this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023.

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “Forward-Looking Statements” on page 2 of this Quarterly Report on Form 10-Q.

COVID-19 Update

In response to the COVID-19 pandemic, we implemented a business continuity plan to respond quickly and provide ongoing guidance so that we could continue offering our clients uninterrupted products, services and support while also protecting our employees. We believe these actions have been successful and that the pandemic, and our responses, have not significantly affected our financial results for the three months ended March 31, 2023.

Refer to Part I, Item 1A. Risk Factors, Risks Related to Our Business in the Company’s Annual Report on Form 10-K filed with the SEC on March 2, 2023 for further discussion of the potential impact of the COVID-19 pandemic on our business.

Financial Risks

The Company maintains cash balances at Silicon Valley Bank (“SVB”), a division of First-Citizens Bank & Trust Company in excess of the FDIC insurance coverage limits. The Company performs periodic evaluation of the relative credit standing of this financial institutions to ensure its credit worthiness. As of March 31, 2023 and December 31, 2022, the Company held cash of approximately $1.4 million and $1.8 million, respectively, in the name of its subsidiaries at bank in Pakistan And Sri Lanka. The banking systems in these countries do not provide deposit insurance coverage. The Company has not experienced any losses on its cash accounts.

Overview

The Company is a healthcare information technology company that provides technology-enabled revenue cycle management and a full suite of proprietary cloud-based solutions to healthcare providers, from small practices to enterprise medical groups, hospitals, and health systems throughout the United States. Our integrated Software-as-a-Service (“SaaS”) platform includes revenue cycle management (“RCM”), practice management (“PM”), electronic health record (“EHR”), business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems.

Our technology-enabled business solutions can be categorized as follows:

  • Technology-enabled revenue cycle management:
  • Revenue Cycle Management (“RCM”) services including end-to-end medical billing, eligibility, analytics, and related services, all of which can be provided utilizing our technology platform and robotic process automation tools or leveraging a third-party system;
  • Medical coding and credentialing services to improve provider collections, back-end cost containment, and drive total revenue realization for our healthcare clients; and
  • Healthcare claims clearinghouse which enables our clients to electronically scrub and submit claims and process payments from insurance companies.
  • Cloud-based software:
  • Electronic Health Records (“EHR”), which are easy to use and sometimes integrated with our business services, and enable our healthcare provider clients to deliver better patient care, streamline their clinical workflows, decrease documentation errors, and potentially qualify for government incentives;
  • Practice Management (“PM”) software and related capabilities, which support our clients’ day-to-day business operations and financial workflows, including automated insurance eligibility software, a robust billing and claims rules engine, and other automated tools designed to maximize reimbursement;
  • Patient Experience Management (“PXM”) solutions designed to transform interactions between patients and their clinicians, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services, contactless digital check-in solutions, messaging, and online appointment scheduling tools;
  • Business Intelligence (“BI”) and healthcare analytics platforms that allow our clients to derive actionable insights from their vast amount of data; and
  • Customized applications, interfaces, and a variety of other technology solutions that support our healthcare clients.
  • Digital health:
  • Chronic care management is a program that supports care for patients with chronic conditions by certified care managers that operate under the supervision of the patient’s regular physician;
  • Remote patient monitoring enables patient data collected outside the clinical setting through remote devices to be fed into their provider’s EHR to enable proactive patient care; and
  • Telemedicine solutions which allow healthcare providers to conduct remote patient visits and extend the timely delivery of care to patients unable to travel to a provider’s office.
  • Healthcare IT professional services & staffing:
  • Professional services consisting of a broad range of consulting services including full software implementations and activation, revenue cycle optimization, data analytic services, and educational training services;
  • Strategic advisory services to manage system evaluations and selection, provide interim management, and operational assessments; and
  • Workforce augmentation and on-demand staffing to support our clients as they expand their businesses, seek highly trained personnel, or struggle to address staffing shortages.

Our medical practice management solutions include:

  • Medical practice management:
  • Medical practice management services for medical providers, including facilities, equipment, supplies, support services, nurses, and administrative support staff.

Our solutions enable clients to increase financial and operational performance, streamline clinical workflows, get better insight through data, and make better business and clinical decisions, resulting in improvement in patient care and collections while reducing administrative burdens and operating costs.

The modernization of the healthcare industry is transforming nearly every aspect of a healthcare organization from policy to providers, clinical care to member services, devices to data, and ultimately the quality of the patient’s experience as a healthcare consumer. We create elegant, user-friendly applications that solve many of the challenges facing healthcare organizations. We partner with organizations to develop customized, best-in-class solutions to solve their specific challenges while ensuring they also meet future regulatory and organizational requirements and market demands.

We are able to deliver our industry-leading solutions at very competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with our team of approximately 500 experienced health industry experts throughout the United States. These experts are supported by our highly educated and specialized offshore workforce of approximately 3,500 team members that are approximately 13% of the cost of comparably educated and skilled workers in the U.S. Our unique business model also allowed us to become a leading consolidator in our industry sector, gaining us a reputation for acquiring and positively transforming distressed competitors into profitable operations of CareCloud.

Adoption of our technology-enabled business solutions typically requires little or no upfront expenditure by a client. Additionally, for most of our solutions and customers, our financial performance is linked directly to the financial performance of our clients, as the vast majority of our revenues are based on a percentage of our clients’ collections. The fees we charge for our complete, integrated, end-to-end solution are very competitive and among the lowest in the industry. We estimate that we currently provide services to approximately 40,000 providers, (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services) practicing in approximately 2,600 independent medical practices and hospitals representing 80 specialties and subspecialties in 50 states. In addition, we serve approximately 150 clients that are not medical practices, but are primarily service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services, and are based, in part, upon estimates where the precise number of practices or providers is unknown.

We service clients ranging from small practices, consisting of one to ten providers, to large practices with over 3,000 providers operating in multiple states, to community hospitals.

Our offshore operations in the Pakistan Offices and Sri Lanka together accounted for approximately 13% and 11% of total expenses for the three months ended March 31, 2023 and 2022, respectively. A significant portion of those foreign expenses were personnel-related costs (approximately 81% for both the three months ended March 31, 2023 and 2022). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. We are able to achieve significant cost reductions and leverage technology to reduce manual work and strategically transition a portion of the remaining manual tasks to our highly-specialized, cost-efficient team in the U.S., the Pakistan Offices and Sri Lanka.

Key Performance Measures

We consider numerous factors in assessing our performance. Key performance measures used by management, including adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share, are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

Adjusted EBITDA excludes the following elements which are included in GAAP net (loss) income:

  • Income tax expense or the cash requirements to pay our taxes;
  • Interest expense, or the cash requirements necessary to service interest on principal payments, on our debt;
  • Foreign currency gains and losses and other non-operating expenditures;
  • Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
  • Depreciation and amortization charges;
  • Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
  • Net loss on lease termination and unoccupied lease charges; and
  • Change in contingent consideration.

26

Set forth below is a presentation of our adjusted EBITDA for the three months ended March 31, 2023 and 2022:

($ in thousands)

Three Months Ended March 31, 2023 2022
Net revenue $30,001 $35,341
GAAP net (loss) income (401) 1,140
Provision for income taxes 65 64
Net interest expense 130 95
Foreign exchange gain (8) (56)
Stock-based compensation expense 1,072 887
Depreciation and amortization 3,038 2,940
Transaction and integration costs 72 102
Net loss on lease termination and unoccupied lease charges 269 158
Change in contingent consideration - (600)
Adjusted EBITDA $4,237 $4,730

Adjusted operating income and adjusted operating margin exclude the following elements that are included in GAAP operating (loss) income:

  • Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
  • Amortization of purchased intangible assets;
  • Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
  • Net loss on lease termination and unoccupied lease charges; and
  • Change in contingent consideration.

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the three months ended March 31, 2023 and 2022:

($ in thousands)

Three Months Ended March 31, 2023 2022
Net revenue $30,001 $35,341
GAAP net (loss) income (401) 1,140
Provision for income taxes 65 64
Net interest expense 130 95
Other income - net (17) (83)
GAAP operating (loss) income (223) 1,216
GAAP operating margin (0.7%) 3.4%
Stock-based compensation expense 1,072 887
Amortization of purchased intangible assets 1,323 1,805
Transaction and integration costs 72 102
Net loss on lease termination and unoccupied lease charges 269 158
Change in contingent consideration - (600)
Non-GAAP adjusted operating income $2,513 $3,568
Non-GAAP adjusted operating margin 8.4% 10.1%

27

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net (loss) income:

  • Foreign currency gains and losses and other non-operating expenditures;
  • Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
  • Amortization of purchased intangible assets;
  • Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
  • Net loss on lease termination and unoccupied lease charges;
  • Change in contingent consideration; and
  • Income tax expense resulting from the amortization of goodwill related to our acquisitions.

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net (loss) income to non-GAAP adjusted net income for the three months ended March 31, 2023 and 2022:

($ in thousands)

Three Months Ended March 31, 2023 2022
GAAP net (loss) income $(401) $1,140
Foreign exchange gain (8) (56)
Stock-based compensation expense 1,072 887
Amortization of purchased intangible assets 1,323 1,805
Transaction and integration costs 72 102
Net loss on lease termination and unoccupied lease charges 269 158
Change in contingent consideration - (600)
Income tax expense related to goodwill 26 36
Non-GAAP adjusted net income $2,353 $3,472

Set forth below is a reconciliation of our GAAP net loss attributable to common shareholders, per share to our non-GAAP adjusted net income per share:

Three Months Ended March 31, 2023 2022
GAAP net loss attributable to common shareholders, per share $(0.28) $(0.19)
Impact of preferred stock dividend 0.25 0.27
Net (loss) income per end-of-period share (0.03) 0.08
Foreign exchange gain 0.00 0.00
Stock-based compensation expense 0.07 0.06
Amortization of purchased intangible assets 0.09 0.11
Transaction and integration costs 0.00 0.01
Net loss on lease termination and unoccupied lease charges 0.02 0.01
Change in contingent consideration 0.00 (0.04)
Income tax expense related to goodwill 0.00 0.00
Non-GAAP adjusted earnings per share $0.15 $0.23
End-of-period common shares 15,592,608 15,062,651
In-the-money warrants and outstanding unvested RSUs 630,094 790,926
Total fully diluted shares 16,222,702 15,853,577
Non-GAAP adjusted diluted earnings per share $0.15 $0.22

28

For purposes of determining non-GAAP adjusted earnings per share, the Company used the number of common shares outstanding at the end of March 31, 2023 and 2022. Non-GAAP adjusted diluted earnings per share was computed using an as-converted method and includes warrants that are in-the-money as of that date as well as outstanding unvested RSUs. Non-GAAP adjusted earnings per share and non-GAAP adjusted diluted earnings per share do not take into account dividends paid on preferred stock. No tax effect has been provided in computing non-GAAP adjusted earnings per share and non-GAAP adjusted diluted earnings per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes.

Key Metrics

In addition to the line items in our consolidated financial statements, we regularly review the following metrics. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

Providers and Practices Served: As of both March 31, 2023 and 2022, we provided services to an estimated universe of approximately 40,000 providers (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 2,600 independent medical practices and hospitals. In addition, we served approximately 150 clients who were not medical practices, but are service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown.

Sources of Revenue

Revenue: We primarily derive our revenues from subscription-based technology-enabled business solutions, reported in our Healthcare IT segment, which are typically billed as a percentage of payments collected by our customers. This fee includes technology-enabled RCM, as well as the ability to use our EHR, practice management system and other software as part of the bundled fee. These solutions accounted for approximately 65% and 66% for the three months ended March 31, 2023 and 2022, respectively. Other healthcare IT services, including printing and mailing operations, group purchasing and professional services, represented 25% for each of the three months ended March 31, 2023 and 2022.

We earned approximately 10% and 9% of our revenue from medical practice management services during the three months ended March 31, 2023 and 2022, respectively. This revenue represents fees based on our actual costs plus a percentage of the operating profit and is reported in our Medical Practice Management segment.

Operating Expenses

Direct Operating Costs. Direct operating cost consists primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facility lease costs, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the consolidated statements of operations.

Selling and Marketing Expense. Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses.

General and Administrative Expense. General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, facility lease costs and insurance, software license fees and outside professional fees.

Research and Development Expense. Research and development expense consists primarily of personnel-related costs, software expense and third-party contractor costs.

Change in Contingent Consideration. Contingent consideration represents the portion of consideration payable to the sellers of some of our acquisitions, the amount of which is based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period.

Depreciation and Amortization Expense. Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to five years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our medical practice management clients is amortized on a straight-line basis over a period of twelve years.

Net Loss on Lease Termination and Unoccupied Lease Charges. Net loss on lease termination represents the write-off of leasehold improvements and gains or losses as the result of lease terminations. Unoccupied lease charges represent the portion of the lease and related costs for that portion of the space that is vacant and not being utilized by the Company. One of the leases that had unoccupied space ended in February 2023. The Company was able to turn back to the landlord one of the other unused facilities effective January 1, 2022.

Interest and Other Income (Expense). Interest expense consists primarily of interest costs related to our line of credit, term loans and amounts due in connection with acquisitions, offset by interest income. Other income (expense) results primarily from foreign currency transaction gains/(losses) and income earned from temporary cash investments.

Income Taxes. In preparing our consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company is forecasting a return to profitability, it incurred losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of March 31, 2023 and December 31, 2022.

Critical Accounting Policies and Estimates

The critical accounting policies and estimates used in the preparation of our consolidated financial statements that we believe affect our more significant judgments and estimates used in the preparation of our consolidated financial statements presented in this Report are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.

Leases:

We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liability (current portion) and operating lease liability (noncurrent portion) in the consolidated balance sheets at March 31, 2023 and December 31, 2022. The Company does not have any finance leases.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

We use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.

Our lease term includes options to extend the lease when it is reasonably certain that we will exercise that option. Leases with a term of less than 12 months are not recorded in the consolidated balance sheet. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the lease and non-lease components as a single lease component. Some leases include escalation clauses and termination options that are factored into the determination of the future lease payments when appropriate.

Capitalized Software Costs:

All of our software is considered internal use for accounting purposes, as we do not market or sell our software. As a result, we capitalize certain costs associated with the creation of internally-developed software for internal use. The total of these costs is recorded in Intangible assets – net in our consolidated balance sheets.

We capitalized costs incurred during the application development stage related to our internal use software. Costs incurred during the application development phase are capitalized only when we believe it is probable that the development will result in new or additional functionality. The types of costs capitalized during the application development phase consist of employee compensation, employee benefits and employee stock-based compensation. Costs related to the preliminary project stage and post-implementation activities are expensed as incurred. Capitalized internal-use software is amortized on a straight-line basis over its estimated useful life when the asset has been placed in service for general availability.

Significant judgments related to internally-developed software include determining whether it is probable that projects will result in new or additional functionality; concluding on when the application development phase starts and ends; and deciding which costs, especially employee compensation costs, should be capitalized. Additionally, there is judgment applied to the useful lives of capitalized software; we have concluded that the useful lives for capitalized internally-developed software is three years.

Company management employs its best estimates and assumptions in determining the appropriateness of the judgments noted above on a project-by-project basis during initial capitalization as well as subsequent measurement. While we believe that our approach to estimates and judgments is reasonable, actual results could differ, and such differences could lead to an increase or decrease in expense.

As of March 31, 2023 and December 31, 2022, the carrying amounts of internally-developed capitalized software in use was $17.0 million and $16.6 million, respectively. The increase in the capitalized software costs represents the continued investment in proprietary technology.

There have been no material changes in our critical accounting policies and estimates from those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023.

Results of Operations

The following table sets forth our consolidated results of operations as a percentage of total revenue for the periods shown:

Three Months Ended March 31, 2023 2022
Net revenue 100.0% 100.0%
Operating expenses:
Direct operating costs 60.3% 64.2%
Selling and marketing 8.7% 6.7%
General and administrative 17.1% 15.8%
Research and development 3.6% 2.8%
Change in contingent consideration 0.0% (1.7%)
Depreciation and amortization 10.1% 8.3%
Net loss on lease termination and unoccupied lease charges 0.9% 0.4%
Total operating expenses 100.7% 96.5%
Operating (loss) income (0.7%) 3.5%
Interest expense - net 0.4% 0.3%
Other income - net 0.0% 0.2%
(Loss) income before provision for income taxes (1.1%) 3.4%
Income tax provision 0.2% 0.2%
Net (loss) income (1.3%) 3.2%

31

Comparison of the three months ended March 31, 2023 and 2022:

($ in thousands)

Three Months Ended March 31, 2023 2022 Change Amount Percent
Net revenue $30,001 $35,341 $(5,340) (15%)

Net Revenue. Net revenue of $30.0 million for the three months ended March 31, 2023 decreased by $5.3 million or 15% from net revenue of $35.3 million for the three months ended March 31, 2022. Revenue for the three months ended March 31, 2023 includes $19.5 million relating to technology-enabled business solutions, $6.6 million related to professional services and $3.0 million for medical practice management services. Revenue was negatively impacted by two large accounts from a 2020 acquisition that were winding down at the time of the acquisition and which transitioned to the systems of their acquirers during 2022. Revenue from these customers for the three months ended March 31, 2023 and 2022 was $1.0 million and $3.6 million, respectively, and is expected to be approximately $1.0 million for the remainder of 2023. Excluding these customers, revenue for the three months ended March 31, 2023 would have been $29.0 million, a decrease of 8.8% from $31.8 million in the three months ended March 31, 2022. (Refer to Forward-Looking Statements disclosure on page 2 of this Form 10-Q.)

($ in thousands)

Three Months Ended March 31, 2023 2022 Change Amount Percent
Direct operating costs $18,107 $22,673 $(4,566) (20%)
Selling and marketing 2,612 2,384 228 10%
General and administrative 5,120 5,585 (465) (8%)
Research and development 1,078 985 93 9%
Change in contingent consideration - (600) 600 100%
Depreciation 492 449 43 10%
Amortization 2,546 2,491 55 2%
Net loss on lease termination and unoccupied lease charges 269 158 111 70%
Total operating expenses $30,224 $34,125 $(3,901) (11%)

Direct Operating Costs. Direct operating costs of $18.1 million for the three months ended March 31, 2023 decreased by $4.6 million or 20% compared to direct operating costs of $22.7 million for the three months ended March 31, 2022. During the three months ended March 31, 2023, salary costs decreased by $2.9 million and outsourcing and processing costs decreased by $1.7 million. The decrease in the salary costs was due to the decrease in the Pakistan exchange rate, a decrease in the U.S. headcount and the redeployment of employees performing functions that were classified as direct operating costs due to lower revenue as well as functions classified as research and development expense for the three months ended March 31, 2023.

Selling and Marketing Expense. Selling and marketing expense of $2.6 million for the three months ended March 31, 2023 increased by $228,000 or 10% from selling and marketing expense of $2.4 million for the three months ended March 31, 2022. The increase was primarily related to additional emphasis on sales and marketing activities.

General and Administrative Expense. General and administrative expense of $5.1 million for the three months ended March 31, 2023 decreased by $465,000 or 8% compared to general and administrative expense of $5.6 million for the three months ended March 31, 2022. The decrease was primarily due to the decrease in salary costs of $519,000.

Research and Development Expense. Research and development expense of $1.1 million for the three months ended March 31, 2023 increased by approximately $93,000 from research and development expense of $985,000 for the three months ended March 31, 2022. The increase was due to the redeployment of employees performing functions that were classified as direct operating costs to functions classified as research and development expense. During the three months ended March 31, 2023 and 2022, the Company capitalized approximately $2.2 million and $2.3 million, respectively, of development costs in connection with its internal-use software.

Change in Contingent Consideration. There was no change in contingent consideration during the quarter ended March 31, 2023 as the balance of contingent consideration was $0 at December 31, 2022. The change of $600,000 for the three months ended March 31, 2022 reflects the estimated decrease in the fair value of the contingent consideration from the medSR acquisition.

Depreciation. Depreciation of $492,000 for the three months ended March 31, 2023, increased by $43,000 or 10% from the depreciation of $449,000 for the three months ended March 31, 2022.

Amortization Expense. Amortization expense of $2.5 million for the three months ended March 31, 2023, increased by $55,000 or 2% from amortization expense of $2.5 million for the three months ended March 31, 2022. The increase in amortization expense was due to the capitalization of intangibles.

Net Loss on Lease Termination and Unoccupied Lease Charges. Net loss on lease termination represents the write-off of leasehold improvements and gains or losses as the result of lease terminations. During the three months ended March 31, 2023, the Miami office lease that we assumed in connection with an acquisition ended and we entered into a new lease arrangement with the landlord for significantly less space. Charges of approximately $71,000 were incurred as a result of vacating the former premises. During the year ended December 31, 2022, a facility lease was terminated in conjunction with the Company ceasing its document storage services resulting in additional costs for the three months ended March 31, 2023, of approximately $45,000. Unoccupied lease charges represent the portion of the lease and related costs for that portion of the space that is vacant and not being utilized by the Company. The Company was able to turn back to the landlord one of the unused facilities effective January 1, 2022.

($ in thousands)

Three Months Ended March 31, 2023 2022 Change Amount Percent
Interest income $20 $5 $15 300%
Interest expense (150) (100) (50) (50%)
Other income - net 17 83 (66) (80%)
Income tax provision 65 64 (1) (2%)

Interest Income. Interest income of $20,000 for the three months ended March 31, 2023 increased by $15,000 from interest income of $5,000 for the three months ended March 31, 2022. The interest income represents interest earned on temporary cash investments and late fees from customers.

Interest Expense. Interest expense of $150,000 for the three months ended March 31, 2023 increased by $50,000 or 50% from interest expense of $100,000 for the three months ended March 31, 2022. Interest expense includes the amortization of deferred financing costs, which was $48,000 and $30,000 during the three months ended March 31, 2023 and 2022, respectively.

Other Income – net. Other income – net was $17,000 for the three months ended March 31, 2023 compared to other income – net of $83,000 for the three months ended March 31, 2022. Other income or expense primarily represents foreign currency transaction gains or losses. These transaction gains or losses result from revaluing intercompany accounts which are denominated in U.S. dollars that represent amounts receivable/payable between the entities. Whenever the exchange rate varies, the gains or losses are recorded in the consolidated statements of operations.

Income Tax Provision. The provision for income taxes was $65,000 for the three months ended March 31, 2023, compared to the provision for income taxes of $64,000 for the three months ended March 31, 2022. As a result of the Company having certain net operating losses with an indefinite life under the current federal tax rules, the federal deferred tax liability was offset against the federal net operating loss to the extent allowable in 2023 and 2022. During 2022, it was determined that for the states that follow the federal rules regarding indefinite life net operating losses, the offset to the state deferred tax liability was $45,000. This amount was recorded during the second quarter of 2022. Subsequently, the state deferred tax liability has been offset against state net operating losses to the extent allowable.

The current income tax expense for the three months ended March 31, 2023 was approximately $39,000, and includes state minimum taxes and foreign income taxes. The Company has incurred cumulative losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax losses difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at March 31, 2023 and December 31, 2022.

Liquidity and Capital Resources

During the three months ended March 31, 2023, there was positive cash flow from operations of $1.0 million and at March 31, 2023, the Company had $8.2 million in cash and positive working capital of $12.3 million. The Company has a revolving line of credit, and as of March 31, 2023, there was $10 million outstanding. As of March 31, 2023, the unused borrowing base was approximately $5.5 million. During the three months ended March 31, 2023, the Company sold 59,773 shares of 8.75% Series B Preferred Stock and raised $1.4 million in net proceeds after fees and expenses.

The following table summarizes our cash flows for the periods presented:

($ in thousands)

Three Months Ended March 31, 2023 2022 Change Amount Percent
Net cash provided by operating activities $1,023 $3,087 $(2,064) (67%)
Net cash used in investing activities (3,039) (2,797) (242) (9%)
Net cash used in financing activities (1,787) (342) (1,445) (423%)
Effect of exchange rate changes on cash (335) (152) (183) (120%)
Net decrease in cash and restricted cash $(4,138) $(204) $(3,934) (1,928%)

The loss before income taxes was $336,000 for the three months ended March 31, 2023, which included $3.0 million of non-cash depreciation and amortization. The income before income taxes was $1.2 million for the three months ended March 31, 2022, which included $2.9 million of non-cash depreciation and amortization.

Operating Activities

Net cash provided by operating activities was $1.0 million and $3.1 million during the three months ended March 31, 2023 and 2022, respectively. This decrease was primarily the result of the decrease in net income of $1.5 million which included the following changes in non-cash items: an increase in depreciation and amortization of $125,000 and an increase in stock-based compensation of $185,000.

Accounts receivable increased by $156,000 for the three months ended March 31, 2023 compared with an increase of $1.6 million for the three months ended March 31, 2022. Accounts payable, accrued compensation and accrued expenses decreased by $2.6 million during the three months ended March 31, 2023 compared with a decrease of $1.1 million for the three months ended March 31, 2022. The contract asset and other assets increased by $699,000 and $518,000, respectively, during the quarter ended March 31, 2023.

Investing Activities

Net cash used in investing activities was $3.0 million and $2.8 million for the three months ended March 31, 2023 and 2022, respectively. Capital expenditures were $835,000 and $544,000 for the three months ended March 31, 2023 and 2022, respectively. The capital expenditures for the three months ended March 31, 2023 and 2022 primarily represented computer equipment purchased and leasehold improvements for the Pakistan Offices. Software development costs of $2.2 million and $2.3 million for the three months ended March 31, 2023 and 2022, respectively, were capitalized in connection with the development of software for providing technology-enabled business solutions.

Financing Activities

Net cash used in financing activities was $1.8 million and $342,000 during the three months ended March 31, 2023 and 2022, respectively. Cash used in financing activities during the three months ended March 31, 2023 included $3.9 million of preferred stock dividends, $236,000 of repayments for debt obligations and $1.1 million of tax withholding obligations paid in connection with stock awards issued to employees. Cash used in financing activities during the three months ended March 31, 2022 included $3.9 million of preferred stock dividends, $251,000 of repayments for debt obligations and $775,000 of tax withholding obligations paid in connection with stock awards issued to employees. During the three months ended March 31, 2022, the Company received net proceeds from the sale of Series B Preferred Stock of $26.6 million of which $20.0 million was used to redeem 800,000 shares of Series A Preferred Stock.

Contractual Obligations and Commitments

We have contractual obligations under our line of credit. We were in compliance with all covenants as of March 31, 2023. We also maintain operating leases for property and certain office equipment. For additional information, see Contractual Obligations and Commitments under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023.

Off-Balance Sheet Arrangements

As of March 31, 2023, and 2022, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. During the first quarter of 2020, a New Jersey corporation, talkMD Clinicians, PA (“talkMD”), was formed by the wife of the Executive Chairman, who is a licensed physician, to provide telehealth services. talkMD was determined to be a variable interest entity (“VIE”) for financial reporting purposes because the entity will be controlled by the Company. As of March 31, 2023, talkMD had not yet commenced operations.

Market risk

As filed, 175 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are a smaller reporting company as defined by 17 C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K.

Controls and procedures

As filed, 2,200 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, based on the Internal Control-Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, as of March 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and l5d-15(f) of the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 1,482 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I—Item 1A. “Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on March 2, 2023, which could materially affect our business, financial condition and/or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows and/or future results.

We Maintain Our Cash at Financial Institutions, Often in Balances That Exceed Federally Insured Limits.

The financial markets recently have encountered volatility associated with concerns about the balance sheets of banks, especially small and regional banks who may have significant losses associated with investments that make it difficult to fund demands to withdraw deposits and other liquidity needs. Although the federal government has announced measures to assist these banks and protect depositors, some banks have already been impacted and others may be materially and adversely impacted. Our business is dependent on bank relationships and we are proactively monitoring the financial health of such bank relationships. Continued strain on the banking system may adversely impact our business, financial condition and results of operations.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-01-01 to 2023-03-31$30.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2023-01-01 to 2023-03-31$1.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2023-01-01 to 2023-03-31−$223.0kus-gaap:OperatingIncomeLoss
Income tax3 months2023-01-01 to 2023-03-31$65.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-01-01 to 2023-03-31−$401.0kus-gaap:NetIncomeLoss
Basic EPS3 months2023-01-01 to 2023-03-31−$0.28us-gaap:EarningsPerShareBasic
Operating cash flow3 months2023-01-01 to 2023-03-31$1.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2023-01-01 to 2023-03-31$835.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Current assetsAt period end2023-03-31$31.5mus-gaap:AssetsCurrent
Total assetsAt period end2023-03-31$131.0mus-gaap:Assets
Current liabilitiesAt period end2023-03-31$19.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-03-31$32.9mus-gaap:Liabilities
Shareholders' equityAt period end2023-03-31$98.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-23-015456. Last ingested by Listed: Nov 5, 2026, 18:58 ET. Listed shows no prices and gives no investment advice.